Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [5449]
News [12652]
Articles [175]
Editorials [5]
Conferences [248]
elearning [17]
Chemo-free treatment for acute promyelocytic leukaemia
Dr Luca Mazzarella - European Institute of Oncology, Milan, Italy
Chemo-free treatment for acute promyelocytic leukaemia ( Dr Luca Mazzarella - European Institute of Oncology, Milan, Italy )
13 Dec 2013
NeoALTTO trial indicates breast cancer patients who had pathologic complete...
Prof Martine Piccart-Gebhart - Jules Bordet Institute, Brussels, Belgium
NeoALTTO trial indicates breast cancer patients who had pathologic complete response had improved event-free and overall survival ( Prof Martine Piccart-Gebhart - Jules Bordet Institute, Brussels, Belgium )
12 Dec 2013
Immune cells in tumours may identify breast cancer patients most likely to...
Dr Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia
Immune cells in tumours may identify breast cancer patients most likely to benefit from trastuzumab ( Dr Sherene Loi - Peter MacCallum Cancer Centre, Melbourne, Australia )
12 Dec 2013
BETH study: highly effective treatment option for patients with HER2 breast...
Dr Dennis Slamon - University of California, Los Angeles
BETH study: highly effective treatment option for patients with HER2 breast cancer ( Dr Dennis Slamon - University of California, Los Angeles )
12 Dec 2013
Screening mammography, over diagnosis and over treatment
Dr Gilbert Welch - Dartmouth College, Hanover, USA
Screening mammography, over diagnosis and over treatment ( Dr Gilbert Welch - Dartmouth College, Hanover, USA )
12 Dec 2013
2013 ecancermedicalscience article highlights
Prof Gordon McVie - ecancer and European Institute of Oncology
2013 ecancermedicalscience article highlights ( Prof Gordon McVie - ecancer and European Institute of Oncology )
11 Dec 2013
Initial phase III results of the first trial in newly diagnosed multiple myeloma
Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, France
Initial phase III results of the first trial in newly diagnosed multiple myeloma ( Dr Thierry Facon - Centre Hospitalier Régional Universitaire de Lille, France )
10 Dec 2013
Lenalidomide promotes CRBN-mediated ubiquitination and degradation of IKZF1 and...
Dr Jan Krönke - Brigham and Women's Hospital, Boston, USA
Lenalidomide promotes CRBN-mediated ubiquitination and degradation of IKZF1 and IKZF3 ( Dr Jan Krönke - Brigham and Women's Hospital, Boston, USA )
8 Dec 2013
Treating ALL patients with T cells targeted for CD19
Dr Laurence Cooper - MD Anderson Cancer Center, Houston, USA
Treating ALL patients with T cells targeted for CD19 ( Dr Laurence Cooper - MD Anderson Cancer Center, Houston, USA )
8 Dec 2013
Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in...
Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA
Long-term functional persistence, B cell aplasia and anti-leukaemia efficacy in refractory B cell malignancies ( Dr Michael Kalos - University of Pennsylvania, Philadelphia, USA )
8 Dec 2013
T cells engineered with chimeric antigen receptor targeting CD19 produce...
Dr Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA
T cells engineered with chimeric antigen receptor targeting CD19 produce significant long-term persistence ( Dr Stephen A. Grupp - University of Pennsylvania, Philadelphia, USA )
8 Dec 2013
Study of the efficacy and safety of siltuximab, an anti-interleukin-6...
Dr Raymond Wong - Chinese University of Hong Kong
Study of the efficacy and safety of siltuximab, an anti-interleukin-6 monoclonal antibody, in patients with multicentric Castleman’s disease ( Dr Raymond Wong - Chinese University of Hong Kong )
8 Dec 2013

More from ecancer

Register with ecancer to receive our newsletter

Register here

Explore patient resources at ecancerpatient

Visit site

Find out more about ecancer and the work we do

About ecancer

Support ecancer's work by making a donation